Profile
Michael N.
Needle worked as Vice President at Celgene Corp.
from 2004 to 2010, Vice President-Clinical Affairs at ImClone LLC from 2000 to 2004, Assistant Professor at Columbia University College of Physicians & Surgeons from 2010 to 2012, Chief Medical Officer at The Multiple Myeloma Research Foundation, Inc. in 2012, Chief Medical Officer at Array BioPharma, Inc. from 2013 to 2014, and Chief Medical Officer at AVEO Pharmaceuticals, Inc. from 2015 to 2021.
He obtained an undergraduate degree from State University of New York at Binghamton and a doctorate from State University of New York at Downstate Medical Center.
Former positions of Michael N. Needle
| Companies | Position | End |
|---|---|---|
| AVEO PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 2021-11-18 |
| ARRAY TECHNOLOGIES, INC. | Chief Tech/Sci/R&D Officer | 2014-09-10 |
The Multiple Myeloma Research Foundation, Inc.
 The Multiple Myeloma Research Foundation, Inc. Miscellaneous Commercial ServicesCommercial Services The Multiple Myeloma Research Foundation, Inc. provides funding for research on myeloma treatment. It provides funding to laboratories worldwide, including compounds and approaches in clinical trials and pre-clinical studies. The firm also facilitates clinical trials through their affiliate organization, the Multiple Myeloma Research Consortium. The company was founded by Karen E. Andrews and Kathryn E. Giusti in 1998 and is headquartered in Norwalk, CT. | Chief Tech/Sci/R&D Officer | 2013-03-31 |
| Columbia University College of Physicians & Surgeons | Corporate Officer/Principal | 2011-12-31 |
| CELGENE | Corporate Officer/Principal | 2009-12-31 |
Training of Michael N. Needle
| State University of New York at Binghamton | Undergraduate Degree |
| State University of New York at Downstate Medical Center | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 5 |
|---|---|
The Multiple Myeloma Research Foundation, Inc.
The Multiple Myeloma Research Foundation, Inc. Miscellaneous Commercial ServicesCommercial Services The Multiple Myeloma Research Foundation, Inc. provides funding for research on myeloma treatment. It provides funding to laboratories worldwide, including compounds and approaches in clinical trials and pre-clinical studies. The firm also facilitates clinical trials through their affiliate organization, the Multiple Myeloma Research Consortium. The company was founded by Karen E. Andrews and Kathryn E. Giusti in 1998 and is headquartered in Norwalk, CT. | Commercial Services |
ImClone LLC
 ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | Health Technology |
Array BioPharma, Inc.
 Array BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Array BioPharma, Inc. is a biopharmaceutical company. Its focus is on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. The company's products are BRAFTOVI and MEKTOVI. Its portfolio includes Binimetinib, Selumetinib, Encorafenib, Filanesib, Ipatasertib, Varltinib, Danoprevir, ARRY-797, Larotrectinib, Tucatinib, ARRY-382, Motolimod, Prexasertib, GDC-0575, LOXO-292, LOXO-195, and AK-1830. The company was founded by Kevin Koch, Anthony D. Piscopio, K. C. Nicolaou, and David L. Snitman in 1998 and is headquartered in Boulder, CO. | Health Technology |
AVEO Pharmaceuticals, Inc.
 AVEO Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA. | Health Technology |
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
- Stock Market
- Insiders
- Michael N. Needle